Marshall Wace, LLP Seagen Inc. Transaction History

Marshall Wace, LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $1.13 Million - $1.28 Million	5,903 Added 1.73%	346,310 $73.5 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $20 Million - $22 Million	106,604 Added 45.6%	340,407 $65.5 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $28.8 Million - $45.8 Million	225,397 Added 2681.38%	233,803 $47.3 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $16 Million - $18.9 Million	-135,956 Reduced 94.18%	8,406 $1.08 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $8.73 Million - $11.6 Million	-64,506 Reduced 30.88%	144,362 $19.8 Million
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $56.2 Million - $92.7 Million	-516,782 Reduced 71.22%	208,868 $37 Million
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $80.4 Million - $106 Million	-671,853 Reduced 48.08%	725,650 $105 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $62.9 Million - $84.1 Million	440,891 Added 46.09%	1,397,503 $216 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $115 Million - $137 Million	807,977 Added 543.6%	956,612 $162 Million
Q2 2021 Aug 13, 2021	SELL	$135.08 - $161.1 $19.4 Million - $23.1 Million	-143,637 Reduced 49.14%	148,635 $23.5 Million
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $20.9 Million - $29 Million	152,025 Added 108.4%	292,272 $40.6 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $22.6 Million - $29.1 Million	137,330 Added 4707.92%	140,247 $24.6 Million
Q3 2020 Nov 16, 2020	BUY	$145.95 - $195.69 $425,736 - $570,827	2,917 New	2,917 $571,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.